



Date: 20 November 2018

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966
123

**Registered Office
and**

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive
Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

NOXOPHARM 2018 AGM INFORMATION

- **Clinical trial update**
- **2019 objectives**
- **Review of Lu-PSMA opportunity**

Sydney, 20 November 2018: Noxopharm (ASX: NOX) provides this reminder about the Company's AGM this Wednesday 21 November, and notifies shareholders that Professor Nat Lenzo will be presenting a review of the opportunity of Lu-PSMA therapy in late-stage prostate cancer.

Dr Lenzo founded Theranostics Australia, now fully owned by GenesisCare, where he remains in the position of clinical director in addition to being a Clinical Associate Professor at The University of Western Australia. GenesisCare is building a series of comprehensive cancer clinics to facilitate research into theranostic treatments such as ¹⁷⁷lutetium-PSMA treatment for prostate cancer. Dr Lenzo will discuss the opportunity in this field.

NOX is collaborating with GenesisCare on the opportunity to bring radio-enhancement into clinical practice.

Separately, NOX is involved in a Phase 1b clinical study at St Vincent's Hospital, Sydney, involving Lu-PSMA therapy where NOX is providing Veyonda[®] and Endocyte Inc is providing ¹⁷⁷lutetium-PSMA-617.

The Noxopharm 2018 AGM will take place at 2pm on Wednesday 21 November at the following location:

Boardroom at the Automic Group
Deutsche Bank Place
Level 5
126 Phillip Street
Sydney NSW 2000

About Noxopharm Group

The Noxopharm Group includes Noxopharm Ltd, Nyrada Inc, and NoxAsia Ltd with offices in Sydney, New York and Hong Kong. The Group's drug pipeline contains 4 drug candidates: Veyonda[®], NYX-104, NYX-205, NYX-330. Veyonda[®] is being developed as an enhancer of chemotherapy and radiotherapy across a range of cancers being treated with both standard external beam radiotherapy and intravenous radionuclide (¹⁷⁷lutetium-PSMA-617) therapy; NYX-104 is a neuroprotectant being

developed to limit secondary brain damage (glutamate-induced excitotoxicity) following ischaemic stroke and concussion; NYX-205 is an anti-inflammatory being developed for the treatment of peripheral neuropathy; NYX-330 is a PCSK9 inhibitor being developed for the treatment of high blood LDL cholesterol levels that fail to respond adequately to statin therapy alone.

Investor & Corporate Enquiries:

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 9299 9690

E: dfranks@fa.com.au

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.